sumatriptan has been researched along with Parkinson Disease in 3 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using [3H]sumatriptan as a radioligand, 5-hydroxytryptamine (5-HT)1B receptors were examined in posterior striatum and midbrain post-mortem tissue sections of 12 patients who had died from representative degenerative movement disorders as compared to nine controls." | 3.70 | 5-HT1B receptor binding in degenerative movement disorders. ( Berciano, J; Castro, ME; Figols, J; Pascual, J; Pazos, A; Romón, T, 1998) |
| "Sumatriptan was injected subcutaneously in 10 de novo parkinsonian patients (aged 58-69 years) and in 9 age-matched normal controls." | 1.30 | Defective 5-HT 1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson's disease. ( Boni, S; Caffarra, P; Chiodera, P; Coiro, V; Saginario, A; Scaglioni, A; Volpi, R, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benedetti, F | 1 |
| Pollo, A | 1 |
| Lopiano, L | 1 |
| Lanotte, M | 1 |
| Vighetti, S | 1 |
| Rainero, I | 1 |
| Volpi, R | 1 |
| Caffarra, P | 1 |
| Scaglioni, A | 1 |
| Boni, S | 1 |
| Saginario, A | 1 |
| Chiodera, P | 1 |
| Coiro, V | 1 |
| Castro, ME | 1 |
| Pascual, J | 1 |
| Romón, T | 1 |
| Berciano, J | 1 |
| Figols, J | 1 |
| Pazos, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo Effect in Children With Attention Deficit Disorder and/or Hyperactivity Disorder[NCT04766580] | 44 participants (Anticipated) | Interventional | 2021-02-17 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for sumatriptan and Parkinson Disease
| Article | Year |
|---|---|
Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses.
Topics: Aged; Analgesia; Attitude to Health; Cognition; Conditioning, Operant; Consciousness; Female; Human | 2003 |
2 other studies available for sumatriptan and Parkinson Disease
| Article | Year |
|---|---|
Defective 5-HT 1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson's disease.
Topics: Aged; Analysis of Variance; Arginine; Case-Control Studies; Growth Hormone-Releasing Hormone; Human | 1997 |
5-HT1B receptor binding in degenerative movement disorders.
Topics: Aged; Aged, 80 and over; Corpus Striatum; Female; Humans; Huntington Disease; Male; Middle Aged; Mov | 1998 |